Does Anthem (Elevance Health) Cover Belsomra (Suvorexant)?

Anthem Formulary Placement for Belsomra

Belsomra appears on the non-preferred brand tier (commonly Tier 3) across most Anthem commercial PPO and HMO formularies. This placement means the drug is covered but carries a higher cost-share than preferred generics like zolpidem or eszopiclone. Anthem's pharmacy benefit manager, IngenioRx, classifies orexin receptor antagonists (ORAs) below generic sedative-hypnotics in its step-therapy hierarchy.

The practical effect of Tier 3 status is a copay that typically falls between $50 and $90 for a 30-day supply, depending on your specific plan design. Some Anthem plans use coinsurance instead of a flat copay, which can push out-of-pocket costs above $100 per fill before you reach your deductible. Your Explanation of Benefits (EOB) document or the Anthem member portal (anthem.com) lists your exact tier structure. Anthem Medicaid managed-care plans in states like Indiana (Anthem MediBlue) and California may carry different formulary rules, so members on government-sponsored Anthem products should verify coverage separately through their state plan formulary 1.

A key detail: Anthem reviews formulary placement annually each January. Drugs can shift tiers or gain new restrictions between plan years. If you had Belsomra covered last year, confirm that coverage persists in your current benefit period.

Prior Authorization Requirements

Anthem requires prior authorization (PA) for every Belsomra prescription on its commercial formularies. Your prescriber, not you, submits the PA request. The process usually takes 48 to 72 hours for a standard review and 24 hours for an urgent (expedited) request.

To approve a PA, Anthem's clinical criteria typically require documentation of all the following: a confirmed diagnosis of insomnia disorder per DSM-5 criteria, failure of or intolerance to at least one preferred generic hypnotic (zolpidem, trazodone, or eszopiclone), and absence of contraindications such as narcolepsy or severe hepatic impairment. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and some Anthem plans now require documentation of a CBT-I referral or trial before approving any pharmacotherapy for chronic insomnia 2.

Suvorexant works through a mechanism distinct from older hypnotics. It blocks orexin receptors OX1R and OX2R, reducing the wakefulness signal rather than broadly sedating the central nervous system. The Herring et al. 2014 trial in The Lancet Neurology (N=3,291) demonstrated that suvorexant improved subjective total sleep time by approximately 20 to 25 minutes versus placebo at week 4, with benefits persisting through 12 months of treatment 3. This distinct mechanism is the clinical rationale for prescribers to cite in the PA letter. The argument is straightforward: a patient who failed a GABA-A modulator may respond to an orexin antagonist because the pharmacology is entirely different.

Your prescriber should include the specific generic agents tried, dates of therapy, documented side effects or lack of efficacy, and the clinical rationale for choosing suvorexant over other covered alternatives. Incomplete PA submissions are the single most common reason for initial denials.

Step Therapy: What Anthem Requires Before Belsomra

Anthem's step-therapy protocol for orexin antagonists mandates a trial-and-fail of at least one preferred generic sleep medication. The most commonly accepted step-therapy agents are zolpidem (immediate or extended release), eszopiclone, and trazodone. Some plans also accept doxepin 3 mg or 6 mg (Silenor) as a qualifying step.

"Trial and fail" has a specific definition for Anthem's utilization management: the patient must have used the step-therapy drug at an adequate dose for a minimum of 14 consecutive days and experienced either inadequate efficacy or intolerable adverse effects. Simply having a documented allergy to one generic does not always satisfy the requirement; Anthem may ask why a second generic was not attempted. A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that 62% of initial PA denials for branded sleep medications across large commercial insurers were linked to incomplete step-therapy documentation rather than true clinical ineligibility 4.

The FDA-approved dosing for Belsomra starts at 10 mg nightly, with an option to increase to 20 mg if 10 mg is tolerated but insufficiently effective 1. Anthem's PA approval typically covers both dose levels. Standard PA approvals last 12 months, after which the prescriber must submit a renewal demonstrating continued clinical need.

How to Appeal an Anthem Denial of Belsomra

An initial PA denial is not the end. Anthem provides a two-level internal appeal process, and federal law under the Affordable Care Act guarantees your right to an external review by an independent review organization (IRO) after internal appeals are exhausted.

For the first-level internal appeal, your prescriber submits a written letter of medical necessity within 180 days of the denial. This letter should directly address the specific reason Anthem cited in its denial. If the denial was "step therapy not completed," the appeal must include pharmacy claims data or chart notes proving the step-therapy drug was tried. If the denial was "not medically necessary," the appeal should reference clinical guidelines and the patient's specific treatment history. The AASM guideline states that pharmacotherapy is appropriate for patients with chronic insomnia who do not respond to or cannot access CBT-I 2.

Second-level appeals go to a different Anthem medical director. If both internal appeals fail, you can request an external IRO review through your state insurance department. According to data from the Kaiser Family Foundation, external reviews overturn insurer denials in roughly 40% to 50% of cases for prescription drug appeals across commercial plans 5.

Timelines matter. Anthem must decide standard appeals within 30 calendar days and expedited appeals within 72 hours. Mark your denial letter's date and track deadlines carefully. Missing the 180-day filing window forfeits your appeal right for that specific denial.

Cost-Reduction Strategies for Belsomra on Anthem

Even with Anthem coverage, the out-of-pocket cost for Belsomra can be significant. Several strategies can reduce what you pay.

The Merck Belsomra Savings Card offers eligible commercially insured patients a copay as low as $0 to $15 per fill, with a maximum annual benefit (typically $3,400 per year). This card works alongside Anthem coverage but cannot be used with government insurance programs like Medicare, Medicaid, or Tricare 1. Patients covered under Anthem commercial plans are generally eligible.

If the savings card is unavailable or you have exhausted its annual cap, consider these alternatives. Cash-pay pricing through GoodRx, RxSaver, or Mark Cuban Cost Plus Drugs can bring 30-day costs to approximately $85, which may be less than your Tier 3 copay in some plan designs. Switching to lemborexant (Dayvigo), a newer dual orexin receptor antagonist, is worth discussing with your prescriber if Anthem places it on a lower tier or has more favorable PA criteria in your specific plan year.

A therapeutic alternative worth considering: the AASM guideline gives a "conditional recommendation" to suvorexant for sleep maintenance insomnia, with the same strength of recommendation assigned to doxepin 3 mg to 6 mg 2. Doxepin at these low doses is available as a generic and sits on Anthem's preferred tier. For patients whose primary complaint is middle-of-the-night awakening rather than sleep onset difficulty, generic low-dose doxepin achieves similar outcomes at a fraction of the cost.

Clinical Profile of Suvorexant: What the Evidence Shows

Suvorexant earned FDA approval in August 2014 for insomnia characterized by difficulty with sleep onset and/or sleep maintenance 1. It was the first orexin receptor antagonist to reach the U.S. market.

The key Herring et al. trial randomized 3,291 adults with insomnia to suvorexant (20 mg or 40 mg, later revised to 15 mg or 20 mg after FDA dose-cap review) or placebo over 12 months. At 3 months, suvorexant 20 mg reduced subjective time to sleep onset by 8 minutes more than placebo and increased total sleep time by 22 minutes versus placebo. The 40 mg dose (not commercially available) showed larger effects but more next-morning somnolence 3. Side effects were generally mild. The most commonly reported adverse events in clinical trials were somnolence (7% vs. 3% placebo), headache, and abnormal dreams.

Suvorexant carries a Schedule IV controlled substance classification, though real-world abuse potential appears low. A post-marketing analysis published in 2020 found no signal of widespread misuse or diversion in the FDA Adverse Event Reporting System database 6. The drug is contraindicated in narcolepsy (blocking orexin in a patient who already lacks orexin signaling would worsen symptoms) and should be used with caution alongside strong CYP3A4 inhibitors, which increase suvorexant plasma levels.

For older adults, the data is encouraging. A subgroup analysis of patients aged 65 and older from the Herring trial showed efficacy similar to the overall population, without excess fall risk 3. This matters because the American Geriatrics Society Beers Criteria lists benzodiazepines and non-benzodiazepine Z-drugs as potentially inappropriate for older adults, making orexin antagonists a pharmacologically cleaner option in this age group 7.

Anthem Coverage for Belsomra vs. Other Insomnia Drugs

Understanding how Anthem positions Belsomra relative to alternatives helps you anticipate coverage decisions.

Zolpidem (generic Ambien) sits on Tier 1 with no PA required. Cost: $5 to $15 per month. Eszopiclone (generic Lunesta) also occupies Tier 1. Trazodone, used off-label for insomnia, is Tier 1 as well and costs under $10 per month. Lemborexant (Dayvigo), the second ORA to reach market, typically shares Tier 3 with Belsomra on Anthem formularies and carries similar PA and step-therapy requirements.

The newest entrant, low-dose doxepin (Silenor), became available as a generic in 2020 and now sits on Tier 1 or Tier 2 on most Anthem plans. A 2019 network meta-analysis in Annals of Internal Medicine compared pharmacotherapies for chronic insomnia and found that suvorexant and doxepin had similar effect sizes for sleep maintenance, while suvorexant showed a modest advantage for sleep onset 8.

Anthem's preferred pathway is clear: try generics first, then move to branded ORAs if generics fail. This is consistent with the AASM guideline, which does not rank suvorexant above generic alternatives in its recommendation hierarchy 2.

Tips for a Successful PA Submission to Anthem

Prescribers who regularly manage Anthem's PA system for sleep medications report that successful submissions share common features.

First, include specific dates. "Patient tried zolpidem" is weak. "Patient took zolpidem 10 mg nightly from March 3, 2026 through March 24, 2026, with documented sleep diary showing mean sleep onset latency of 45 minutes and two nightly awakenings" is strong. Second, attach supporting documentation: sleep diaries, actigraphy data, or polysomnography results if available. Third, cite the mechanism-of-action argument explicitly. State that the patient failed a GABA-A modulator and that an orexin antagonist targets a fundamentally different pathway. Fourth, note any comorbidities that make generic hypnotics riskier. A history of substance use disorder, for example, makes the low-abuse-potential profile of suvorexant clinically relevant, and Anthem reviewers are trained to weigh this.

The FDA label recommends a starting dose of 10 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining 1. Prescribers should specify the intended starting dose in the PA request, as Anthem may flag requests that begin at 20 mg without a documented trial at the lower dose.